Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of Clinical Nursing (JCN)
COVID-19, as we know, is a global health crisis that has had a significant impact on the mental health of nurses. Until now, no studies were available on factors affecting the psychological well-being of nurses in Turkey during the pandemic. These insights are crucial because any impairments to nurses’ psychological well-being can negatively affect both the quality of care they provide and their overall performance. In an effort to fill this knowledge gap, the study used a descriptive, correlational, and cross-sectional design. By adhering to the STROBE reporting guideline checklist, the researchers meticulously compiled their findings. A sample of 295 nurses from a Health Application and Research Center in Turkey, who voluntarily participated through social media tools, formed the study group. Data collection occurred between June and August 2020 using Google forms. Instruments employed included a Sociodemographic Characteristics Form, the COVID-19 Phobia Scale (C19P-S), the Work-Life Balance (WLB) Scale, and the Psychological Well-Being (PWB) Scale. The team employed stepwise multiple linear regression analysis to pinpoint factors affecting psychological well-being. Unsurprisingly, the study found that both the work-life balance and psychological well-being of nurses were negatively affected during the COVID-19 pandemic. Most nurses exhibited mild-to-moderate levels of COVID-19 phobia. Among the […]
Nursing May 30th 2023
DDW News
Let’s delve into the groundbreaking application of endoscopic electroporation and semaglutide that’s changing the game in diabetes management. First off, the EMINENT study is unveiling a revolutionary approach in treating type 2 diabetes. This method combines endoscopic electroporation, known as ReCET, with the medication semaglutide. The main goal is to reduce or potentially eliminate the need for insulin, revolutionizing glycemic control. The innovative ReCET procedure employs electroporation to ablate the superficial layer of mucosa in the small intestine. Researchers hope that by rejuvenating the duodenal lining and employing a GLP-1 receptor agonist, they could address insulin resistance, the fundamental problem in type 2 diabetes. Interestingly, ReCET doesn’t use extreme temperatures to ablate intestinal tissue. Rather, it uses a pulsed electric field, yielding precise control and limited depth of penetration. This method disrupts the cellular membrane of the mucosa and superficial submucosa, triggering natural cell death within a day, thereby significantly minimizing the risk of complications. A single-arm pilot study conducted as part of EMINENT involved 14 patients with type 2 diabetes using long-acting basal insulin. All patients underwent the ReCET procedure and started on semaglutide two weeks later. Researchers noted the feasibility and safety of ReCET, with a 100% success […]
Endocrinology, Diabetes, Metabolism May 24th 2023
Annals of Internal Medicine
Let’s delve into the complexity of mask effectiveness against SARS-CoV-2 in diverse settings. Debate rages on about optimal mask use for COVID-19 prevention. This trial takes a fresh look at the issue. It evaluates N95, surgical, and cloth masks in preventing SARS-CoV-2 infections. The team sourced data from MEDLINE, EMBASE, and medRxiv. They also scanned relevant reference lists. They selected randomized trials and observational studies. These studies increased mask use and controlled for confounding factors in assessing SARS-CoV-2 infection risk. Two investigators carried out the data extraction process. They carefully abstracted data from each study and evaluated its quality. Their efforts resulted in the inclusion of three randomized trials and 21 observational studies. Evidence from two trials and seven studies points to a possible reduction in SARS-CoV-2 infection risk through mask use in community settings. Despite this, observational studies failed to provide sufficient evidence for other mask comparisons due to methodological inconsistencies. In routine patient care settings, one new trial and four studies indicated comparable infection risk between surgical masks and N95 respirators. However, the study couldn’t disregard the potential beneficial effects of N95 respirators. Yet, several limitations cloud these findings. These include a limited number of randomized trials, methodological […]
All Specialties May 24th 2023
Multiple Sclerosis News Today
Unveil the potential ramifications of a pro-inflammatory diet on MS patients, especially concerning relapse rate and inflammatory brain lesions. Recent research from the University of Tasmania offers key insights into diet and MS. Essentially, a pro-inflammatory diet may boost relapse rates and inflammatory brain lesions. This highlights the potential impact of such a diet on MS patients. Notably, this diet didn’t influence disability progression or chronic inflammation lesions. MS, defined as a chronic autoimmune disease, harms nerve cells. Significantly, lifestyle modifications may enhance MS symptoms and outcomes. A diet high in fats and proteins, known as a pro-inflammatory diet, could heighten inflammation. Conversely, incorporating anti-inflammatory foods like turmeric, fiber, and beta-carotene may benefit those with inflammatory diseases. The Dietary Inflammation Index (DII), measures diet-related impacts on chronic inflammation. Importantly, higher DII scores imply elevated systemic inflammation, which correlates with increased cardiovascular disease and colorectal cancer risk. The researchers used data from 190 participants in the AusLong Study, all later diagnosed with MS. Participants completed a food frequency questionnaire, from which DII scores were computed. Importantly, for each one-unit DII increase, relapse risk rose by 18%. Strikingly, those in the highest energy-adjusted scores quartile were 2.24 times more likely to relapse. […]
Internal Medicine May 23rd 2023
Oncology Nurse Advisor
Permissive cardiotoxicity strategy could enhance trastuzumab treatment outcomes in HER2-positive breast cancer patients, despite requiring more research into its long-term safety. A study conducted at McMaster University and published in The Oncologist explored the feasibility of a permissive cardiotoxicity strategy in patients with HER2-positive breast cancer undergoing trastuzumab treatment. Although trastuzumab significantly improves outcomes in these patients, up to 4% of them may experience cardiac dose-limiting toxicity (cDLT), resulting in therapy discontinuation, which can negatively impact patient outcomes. The researchers employed a retrospective cohort study of 51 patients who had been referred to the cardio-oncology service between January 2016 and May 2021 for left ventricular dysfunction after trastuzumab administration. Notably, a permissive cardiotoxicity strategy was applied, which allows the continuation of trastuzumab therapy while closely monitoring mild to moderate cardiotoxicity. The primary outcomes for this study were left ventricular (LV) function and completion of an entire course of trastuzumab. Astonishingly, 92% of patients (47 out of 51) were able to complete their full course of HER2-targeted therapy without experiencing cDLT. However, 6% developed cDLT during trastuzumab treatment, and even after discontinuation, they were more likely to experience persistent cardiotoxicity. Interestingly, despite most patients regaining their LV function post-treatment, 14% persisted […]
Obstetrics & Gynecology May 22nd 2023
The New England Journal of Medicine
The study in question presents a prospective randomized trial that evaluated the efficacy and safety of percutaneous tricuspid transcatheter edge-to-edge repair (TEER) in patients with severe tricuspid regurgitation. Conducted across 65 centers in North America and Europe, 350 patients were randomized into two equal groups, with one group undergoing TEER and the other receiving conventional medical therapy. The primary composite endpoint encompassed factors such as all-cause mortality or tricuspid valve surgery, heart failure hospitalization, and improvement in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Also evaluated were the severity of tricuspid regurgitation and the safety profile of TEER. The trial concluded with results favoring the TEER group (win ratio, 1.48; 95% CI, 1.06-2.13; P=0.02), although rates of death, tricuspid-valve surgery, and heart failure hospitalization showed no significant difference between the two groups. The TEER group exhibited a marked improvement in KCCQ scores compared to the control group (mean change 12.3±1.8 vs. 0.6±1.8; P<0.001) and a significant reduction in the severity of tricuspid regurgitation at the 30-day mark (87.0% TEER group vs. 4.8% control group with tricuspid regurgitation of no greater than moderate severity; P<0.001). The safety profile for TEER was reassuring, with 98.3% of patients […]
Cardiology May 22nd 2023